Cargando…
Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence
The purpose of this review is to assess whether dietary fish oil supplements can be appropriate for patients with elevated triglycerides and cardiovascular risk based on a comprehensive analysis of their composition, and level of regulatory oversight. RECENT FINDINGS: Approximately 19 million people...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069411/ https://www.ncbi.nlm.nih.gov/pubmed/32022752 http://dx.doi.org/10.1097/MOL.0000000000000665 |
_version_ | 1783505773736755200 |
---|---|
author | Sherratt, Samuel C.R. Lero, Michael Mason, R. Preston |
author_facet | Sherratt, Samuel C.R. Lero, Michael Mason, R. Preston |
author_sort | Sherratt, Samuel C.R. |
collection | PubMed |
description | The purpose of this review is to assess whether dietary fish oil supplements can be appropriate for patients with elevated triglycerides and cardiovascular risk based on a comprehensive analysis of their composition, and level of regulatory oversight. RECENT FINDINGS: Approximately 19 million people in the United States take fish oil supplements, many for the purpose of treating or preventing heart disease. Unlike prescription products, fish oil supplements are classified as food by the Food and Drug Administration (FDA) and are not required to undergo manufacturing oversight or clinical testing. Analysis of widely used dietary fish oil supplements show that they may have lower amounts of ω-3 than advertised as well as significant levels of saturated fat and oxidized oils which actually may contribute to dyslipidemia. Clinical outcome trials have failed to show a consistent cardiovascular benefit with fish oil supplements and other low-dose mixed ω-3 fatty acids. SUMMARY: In light of limited regulatory oversight and evidence of quality concerns, dietary fish oil supplements are not an appropriate substitute for FDA approved prescription ω-3 fatty acids for their indicated use in treatment of elevated triglycerides or the prevention of cardiovascular events. |
format | Online Article Text |
id | pubmed-7069411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-70694112020-03-25 Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence Sherratt, Samuel C.R. Lero, Michael Mason, R. Preston Curr Opin Lipidol GENETICS AND MOLECULAR BIOLOGY: Edited by Robert A. Hegele The purpose of this review is to assess whether dietary fish oil supplements can be appropriate for patients with elevated triglycerides and cardiovascular risk based on a comprehensive analysis of their composition, and level of regulatory oversight. RECENT FINDINGS: Approximately 19 million people in the United States take fish oil supplements, many for the purpose of treating or preventing heart disease. Unlike prescription products, fish oil supplements are classified as food by the Food and Drug Administration (FDA) and are not required to undergo manufacturing oversight or clinical testing. Analysis of widely used dietary fish oil supplements show that they may have lower amounts of ω-3 than advertised as well as significant levels of saturated fat and oxidized oils which actually may contribute to dyslipidemia. Clinical outcome trials have failed to show a consistent cardiovascular benefit with fish oil supplements and other low-dose mixed ω-3 fatty acids. SUMMARY: In light of limited regulatory oversight and evidence of quality concerns, dietary fish oil supplements are not an appropriate substitute for FDA approved prescription ω-3 fatty acids for their indicated use in treatment of elevated triglycerides or the prevention of cardiovascular events. Lippincott Williams & Wilkins 2020-04 2020-03-05 /pmc/articles/PMC7069411/ /pubmed/32022752 http://dx.doi.org/10.1097/MOL.0000000000000665 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | GENETICS AND MOLECULAR BIOLOGY: Edited by Robert A. Hegele Sherratt, Samuel C.R. Lero, Michael Mason, R. Preston Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence |
title | Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence |
title_full | Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence |
title_fullStr | Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence |
title_full_unstemmed | Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence |
title_short | Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence |
title_sort | are dietary fish oil supplements appropriate for dyslipidemia management? a review of the evidence |
topic | GENETICS AND MOLECULAR BIOLOGY: Edited by Robert A. Hegele |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069411/ https://www.ncbi.nlm.nih.gov/pubmed/32022752 http://dx.doi.org/10.1097/MOL.0000000000000665 |
work_keys_str_mv | AT sherrattsamuelcr aredietaryfishoilsupplementsappropriatefordyslipidemiamanagementareviewoftheevidence AT leromichael aredietaryfishoilsupplementsappropriatefordyslipidemiamanagementareviewoftheevidence AT masonrpreston aredietaryfishoilsupplementsappropriatefordyslipidemiamanagementareviewoftheevidence |